Ai-driven optimization of novel bed bug repellents
Discover AI-driven molecules that outperform DEET as bed bug repellents. These molecules show efficacy against multiple pests and are suitable for formulation into consumer products.
Overview
TropIQ Health Sciences has harnessed advanced machine learning models to identify novel molecules that effectively repel bed bugs, mosquitoes, ticks, and fleas. These innovative compounds outperform the market standard DEET, offering a more efficient solution for pest control. Designed for indoor use, these molecules can be formulated into sprays or washing powders, providing versatile applications.
Technical specifications
- Machine Learning Models: Utilized to predict and validate repellency across diverse compounds with a 6% hit rate.
- Multi-Species Efficacy: Proven effectiveness against bed bugs, mosquitoes, ticks, and fleas.
- Structure-Activity Relationships: Validated for high potency and efficacy.
- Physicochemical Properties: Suitable for formulation into consumer products.
- Source of Compounds: Derived from commercial sources, facilitating repurposing.
Technology readiness level
The technology is at TRL 4, indicating validated lab-scale efficacy. The next step involves formulation design and efficacy testing to meet regulatory and performance benchmarks, paving the way for commercialization. TropIQ seeks partnerships for further development and testing.
About TropIQ Health Sciences
TropIQ Health Sciences is a biotechnology company that provides a technology platform for the discovery and development of interventions against vector-borne and insect-borne diseases. Based in Nijmegen, the Netherlands, the company combines expertise in microbiology, parasitology, and entomology with laboratory automation, data science, and machine learning. Their platform enables high-throughput screening and the identification of small molecules and biological candidates to combat pathogens such as those causing malaria, dengue, and tick-borne diseases. By integrating molecular, genetic, and cell biological technologies, TropIQ supports the optimization of lead molecules and the investigation of their mechanisms of action.
The company serves as a partner in global health efforts, focusing on interventions that address diseases affecting humans and animals, particularly in low and middle-income countries. TropIQ offers contract research services that span from assay development and parasite biomass production to in vivo arthropod testing and the evaluation of novel repellents. As a spin-off from Radboudumc, the company has received support from organizations including the Bill & Melinda Gates Foundation to advance agricultural and public health research, such as developing systems to combat livestock ticks and identifying innovative drugs and vaccines to mitigate the impact of disease-transmitting arthropods.
delivered to your inbox.